IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12234244 B1

PDFFull Text
Date of Patent:
Feb. 25, 2025

Filed:

Apr. 08, 2022

Substituted piperazines as inhibitors of kras g12c

Applicant:

Araxes Pharma Llc, San Diego, CA (US);

Inventors:

Liansheng Li, San Diego, CA (US);

Jun Feng, San Diego, CA (US);

Tao Wu, Carlsbad, CA (US);

Pingda Ren, San Diego, CA (US);

Yi Liu, San Diego, CA (US);

Yuan Liu, San Diego, CA (US);

Yun Oliver Long, San Diego, CA (US);

Assignee:

Araxes Pharma LLC, San Diego, CA (US);

Attorney:

Seed IP Law Group LLP

Primary Examiner:

Douglas M Willis

Int. Cl.
CPC ...
A61K 31/517 (2006.01); C07D 215/46 (2006.01); C07D 215/54 (2006.01); C07D 217/22 (2006.01); C07D 239/84 (2006.01); C07D 239/94 (2006.01); C07D 239/95 (2006.01); C07D 241/44 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 403/04 (2006.01); C07D 409/04 (2006.01); C07D 487/04 (2006.01); C07D 495/04 (2006.01);
U.S. Cl.
CPC ...
C07D 495/04 (2013.01); C07D 215/46 (2013.01); C07D 215/54 (2013.01); C07D 217/22 (2013.01); C07D 239/84 (2013.01); C07D 239/94 (2013.01); C07D 239/95 (2013.01); C07D 241/44 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 403/04 (2013.01); C07D 409/04 (2013.01); C07D 487/04 (2013.01);
Abstract

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, have the following structure: wherein A, L, L, Q, R, R, R, R, R, R, R, R, Y, and Z are as exemplified herein. Pharmaceutical compositions comprising such compounds, methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, and methods associated with preparation of such compounds are also provided.

Find Patent Forward Citations

Loading…